Vogelgrippe? Die Aktie! - 500 Beiträge pro Seite

[toptiper]

Avian Flu gerät aktuell mehr und mehr in den Focus der internationalen Presse - Genomed hat am 15.01.04 die untern ageführte Mitteilung veröffentlicht - z.Z. ist die Vogelgrippe noch nicht im Focus der Masse der Anleger - sollte jedoch die Ausbreitung im asiatischen Raum in diesem Tempo weitergehen, so dürfte hier ein Hype bevorstehen (siehe Weltraumaktien + Bush, BSE-Fall USA + Hype) - ich habe sehr lange recherchiert - mehr oder weniger wirksame (riskante) Medikamente befinden sich bei GlaxoSmith + Roche im Sortiment - aber Vorsicht - die Aktie ist nicht in Deutschland handelbar und ist ein PinkS-Wert!
Auch die älteren News lesen sich sehr vielversprechend!

Die News vom 15.01.04

GenoMed`s Universal Approach to Viral Diseases Includes Avian Flu (Bird Flu) As Well as SARS and Influenza A
Thursday January 15, 2:19 pm ET


ST. LOUIS, Jan. 15 /PRNewswire-FirstCall/ -- GenoMed Inc. ("the Company" or "GenoMed") (Pink Sheets: GMED - News) announced today that its treatment approach ought to be suitable for all currently untreatable viral diseases, including avian flu (bird flu). Vietnam has recently had a number of deaths from bird flu, and has started exterminating its chickens, as China has done with civet cats. The World Health Organization has just declared a state of urgency.
Enter GenoMed. In results to be published next month, the Company achieved an 88% cure rate against West Nile virus encephalitis this past September (2003). Obviously, a cure makes trying to kill all the mosquitoes in the world unnecessary. For an independent assessment of our case series, please see the recent article by Steve Mitchell, UPI Medical Correspondent, available at: http://washingtontimes.com/upi-breaking/20031204-040206-6908… .

GenoMed believes that the reason people die from viruses they`ve never been exposed to before is not because the virus is growing out of control in their body, turning it into a kind of liquefied Petri dish. But this is the prevailing view among virologists. Rather, GenoMed believes people get in trouble from viruses when their innate immune response over-reacts. How else explain that coronaviruses which we`re used to as a species, the so-called "human" coronaviruses, are shed for weeks from people with head-colds, whereas infection with a coronavirus new to the species like SARS carries a 20% mortality? The SARS coronavirus doesn`t contain any killer enzymes that liquefy lung tissue. It just contains some new protein antigens that make the host`s immune response go crazy.

To borrow a phrase from the gun lobby: viral replication doesn`t kill; the host`s immune response does.

Never before seen lung viruses like the bird flu virus, this year`s influenza A virus, respiratory syncytial virus (RSV) in children, and SARS all cause death due to an acute respiratory distress-like syndrome (ARDS). ARDS is caused by an overly exuberant innate immune response in the lung. The host`s initial immune response, if mild or excessive, not viral overgrowth, determines whether the host lives or dies.

For novel viruses like this year`s influenza A virus, the SARS coronavirus, the bird flu virus, and West Nile virus, the body has no memory of having ever seen the virus, so it can`t coat the virus with pre-existing antibodies, nor calm the rage of immune effector cells (monocyte/macrophages) with soothing suppressor T cells. The whole point of vaccination is to have pre-existing antibodies and T cells with "memory" for the virus present when the virus actually infects the host. This routinely occurs for viruses that co-habit with humans. We`re all exposed to them. Vaccination creates suppressor T cells with specific memory for the virus, as well as coating antibodies. Without a competent suppressor limb, the immune response can become unbalanced, leading to organ damage in the host.

GenoMed believes it has discovered a way to accomplish the equivalent of vaccination against most viruses, a kind of "universal vaccine" against most viral diseases. The method involves blocking angiotensin II, using drugs already known to be extremely safe from their use in hundreds of millions of patients worldwide since 1980.

Angiotensin II is important in getting the innate immune response started, because angiotensin I-converting enzyme (ACE), the enzyme which produces angiotensin II, is expressed on macrophages and T cells when these cells get activated. All immune cells, including macrophages, T and B cells, and neutrophils, contain type 1 receptors for angiotensin II. Blocking angiotensin II production with a suitable ACE inhibitor at a suitable dose, or the action of angiotensin II at type 1 receptors with an angiotensin II receptor blocker (ARB), is therefore expected to tone down the host`s initial immune response. This is equivalent to what a good vaccine does. GenoMed`s approach should decrease mortality from most viral infections, and may even hasten recovery from the common cold.

The patient`s blood pressure should be the guide as to whether an ACE inhibitor or an ARB is chosen.

Said Dr. David Moskowitz, GenoMed`s Chief Medical Officer and CEO, "We simply cannot kill all the animals in the world, nor is it ethical to quarantine everybody who`s sick and leave them to die. Instead, we need to learn to live with new viruses. Anyone in the world can test our approach for themselves; the trial is completely free from our end. This message is especially important for people getting sicker rather than recovering as fast as expected from the flu. The Internet now makes it possible for anybody to enroll in our flu trial at any time of day or night anywhere in the world, simply by going to our website and clicking on "Flu trial." They`ll need to enter their email address so that we can follow up with them. Then they`ll be able to download the 2 documents they`ll need to show their physician so as to get started on our trial. A family member could easily do this for a child getting worse with the flu, for example."

The drugs GenoMed uses are safe enough to allow for their preventive use, and are available in every corner drug store. Most physicians are already comfortable using them to treat high blood pressure. Angiotensin II receptor blockers at extremely low doses appear to be effective against overactivity of the immune system without lowering blood pressure at all.

To volunteer for one of GenoMed`s free clinical trials, go to www.genomedics.com .

About GenoMed

GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission is to improve the public`s health by identifying the molecular pathways that cause disease. A St. Louis Business Journal article ( http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… ) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases.

For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-977-0115, FAX [phone], email: [e-mail] , or visit GenoMed at www.genomedics.com .

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the Company`s) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether GenoMed`s approach will prove to be as effective in human cases of the avian flu, influenza A, and SARS as it already has been against West Nile virus encephalitis; (b) whether GenoMed`s server will hold up to international demand; (c) whether we will have sufficient financing to conduct our research and development; and (d) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

[Catchup]

Wie? Grippe vom vögeln...? Erst SARS und nun das.....

catchup

[toptiper]

Gegen die "Vögelgrippe" hilft nur dies:



Nach dem Anblick hat sich die Ansteckungsgefahr in Luft aufgelöst

[thebull 2]

Fünfter Mensch in Vietnam an Vogelgrippe gestorben
Hanoi (dpa) - Die WHO ist besorgt über den Ausbruch der Vogelgrippe in mehreren asiatischen Ländern: Ein achtjähriges Mädchen ist als fünfter Mensch in Vietnam an der Tierseuche gestorben. Bei dem Kind sei der hoch ansteckende Virustyp H5N1 nachgewiesen worden, bestätigte die Weltgesundheitsorganisation in Hanoi. Dies könne bedeuten, dass sich der auch für Menschen bedrohliche Erreger in den Vögeln dieses Erdteils festsetze. Außer in Vietnam grassiert die Vogelgrippe in Südkorea, Japan und Taiwan.

[Catchup]

Können Katzen auch die Vögelgrippe bekommen? Mir gruselt....

catchup

[toptiper]

Heute + 22%

Hat jemand auf meine gestrige Empfehlung gehört

Im Zuge der Vogelgrippe dürfte der Hype erst noch bevorstehen

[thebull 2]

bericht zur vogelgrippe jetzt auf rtl

[thebull 2]

yahoonews zur aktie unter http://biz.yahoo.com/prnews/040115/cgth064_1.html

[thebull 2]

WHO besorgt über Ausbreitung von Vogelgrippe

Zuerst sterben Hühner in Massen, dann springt der Erreger plötzlich auf den Menschen über. Was 1997 in Hongkong geschah, scheint sich nun in mehreren asiatischen Ländern gleichzeitig zu wiederholen. Reisende sollen Geflügelmärkte meiden.




Geflügelmarkt in Guangzhou, China.
Foto: AP



Ein acht Jahre altes Mädchen ist das fünfte Todesopfer der Vogelgrippe-Epidemie in Vietnam. Bei dem Kind sei der hoch ansteckende Virustyp H5N1 nachgewiesen worden, bestätigte die Weltgesundheitsorganisation (WHO).

Die Organisation zeigte sich zugleich besorgt über den zeitgleichen Ausbruch der Tierseuche in mehreren asiatischen Ländern, der bislang ohne Beispiel sei.

Dies könne bedeuten, dass sich der auch für Menschen bedrohliche Erreger H5N1 in den Vögeln dieses Erdteils festsetze.

An der Vogelgrippe waren in den vergangenen Wochen in Vietnam mehr als eine Million Hühner verendet. Darüber hinaus sind Ausbrüche bei Tieren in Südkorea, Japan und Taiwan gemeldet worden.

Die tatsächliche geographische Ausdehnung der Vogelepidemie sei aber möglicherweise noch nicht vollständig bekannt, warnte die WHO in Genf.

Reisende sind nach Auskunft des Hamburger Bernhard-Nocht-Instituts für Tropenmedizin bislang nicht gefährdet, sofern sie Geflügelmärkte und andere Kontakte zu Vögeln meiden.

Den Ausbruch in Vietnam bezeichnete die WHO als besonders beunruhigend, weil dort mehrere Faktoren zusammen kommen könnten, die in der Vergangenheit bereits weltweite Grippe-Epidemien befördert hätten.

Dazu gehöre vor allem, dass zeitgleich mit dem aggressiven und leicht mutierenden Vogelgrippevirus H5N1 auch menschliche Influenzaviren zirkulierten.


mehr zum Thema

Vogelgrippe
Vietnam will zehn Millionen Vögel töten

Sars
Entwarnung in Hongkong

Gefährliche Mikroben
Das Grauen aus der Entenbrust






H5N1 besitze die Tendenz, Gene anderer Grippeviren aufzunehmen. Ein solches neu zusammengesetztes Virus könnte nach Befürchtung von Experten auch von Mensch zu Mensch übertragen werden, nicht nur von Vögeln auf Menschen.

Bislang sei allerdings kein fremdes Erbgut in den aktuell isolierten H5N1-Viren nachgewiesen worden, betonte die WHO.

Trotz der Schwere kann der aktuelle Ausbruch nach WHO-Einschätzung eingedämmt werden, sofern alle als Überträger in Frage kommenden Geflügelbestände rasch vernichtet würden.

Auf diese Weise seien bereits früher in anderen Ländern effektiv Epidemien gestoppt worden.

H5N1 ist nach WHO-Angaben das einzige Vogelgrippevirus, das bislang schwere Infektionen beim Menschen verursacht hat. So starben daran beispielsweise 1997 in Hongkong 6 von 18 Infizierten.

[thebull 2]

übrigens sterben alle 5 jahre ca 50 millionen menschen an folgen einer grippe

[thebull 2]

[strategie06]

Diese News wurde bisher vergessen. Dem Kurs hatte sie gut getan, jetzt schon auf 0,10.

ST. LOUIS, Jan. 20 /PRNewswire-FirstCall/ -- GenoMed Inc. ("the Company" or "GenoMed")(National Quotation Bureau`s Pink Sheets Symbol GMED) announced today that the Company has secured an additional $900,000 in equity financing from Advanced Optics Electronics, Inc. (OTC Bulletin Board: ADOT - News). This financing is separate and in addition to the up to $500,000 financing secured by the Company in October 2003 (see company press release of October 22, 2003).
ADVERTISEMENT

Terms of the Agreement call for a capital investment into GenoMed of $900,000 in exchange for restricted common shares of GenoMed at a 25% discount to market. The financing Agreement will be available for public review within the Company`s next filings with the Securities and Exchange Commission (SEC) at www.sec.gov .

Dr. David Moskowitz, GenoMed`s CEO and Chief Medical Officer said, "I am pleased to report to the shareholders of our Company that we have secured financing that will allow the Company to accelerate our search for new disease genes, while also spreading the word about diseases we can manage based on the `master` disease gene we`ve already found."

Dr. Moskowitz continued, "The capital infusion will be spent mostly on genotyping, sample collection, and data analysis. We shall also commit some money to educating the public about being able to prevent 90% of kidney failure in this country, as well as significantly delay the progression of emphysema. Positive results for West Nile virus encephalitis, psoriasis, and late stage pancreatic cancer will be published soon. Trials are in progress for a number of diseases, including SARS and the flu."

Dr. Moskowitz ended by saying, "I believe this transaction is extremely fair. It limits the dilution to our existing shareholders as the Company moves forward."

About GenoMed

GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article ( http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… ) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases. It has an aggressive plan to find hundreds of additional disease-predisposition genes within the next 24 months.

For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-977-0115, FAX [phone], email: [e-mail] , or visit GenoMed at www.genomedics.com .

[GoldenStock]

Wie wärs auch mit SYNBIOTICS ( SBIO ) sind auch im Bereich
der Veträniermedizin für Tiere tätig, und sind bisher auch nicht gelaufen. (Siehe www.synbiotics.com - oder www.synbioitcs.fr) Kurs akutell bei nur 0,47 $.
Auch eine der Aktien die sehr bald "starten" werden.

Gruß
GoldenStock

[thebull 2]

Roche: Mittel gegen Vogelgrippe? Aktuelle Nachrichten

30.01.2004


Der Schweizer Roche-Konzern hat heute bekannt gegeben, dass sein Präparat Tamiflu möglicherweise gegen die in Asien wütende Vogelgrippe wirksam sein könnte. Der Grund dafür sei die genetische Verwandtschaft des entsprechenden Erregers mit herkömmlichen Virusgrippen, die mit dem Wirkstoff seit längerem erfolgreich behandelt werden.

Auch die Weltgesundheitsorganisation habe in einer Stellungnahme den Einsatz von Tamiflu unterstützt. Das Mittel soll den Betroffenen zu einem vergünstigten Preis zur Verfügung gestellt werden. Der Vogelgrippe sind in Asien bereits 8 Menschen zum Opfer gefallen, die überwiegend in Hühnerfarmen beschäftigt waren. Vor allem für Thailand und Vietnam werden durch Hühnerfleisch-Embargos und Einbrüche im Tourismus bereits Schäden in beträchtlicher volkswirtschaftlicher Größenordnung prognostiziert.

Ein weiterer Anbieter eines möglicherweise wirksamen Präparats sei möglicherweise der britische Mitstreiter GlaxoSmithkline. Das Volumen derartiger Grippe-Präparate, die bei der Virusbekämpfung bei bestimmten Proteinen ansetzen, liegt bei geschätzten 2 Milliarden Dollar weltweit.

Die Roche-Aktie notierte heute in Frankfurt unverändert bei 83 Euro.

[strategie06]

Bird Flu Hits U.S.; GenoMed Believes It Has Cure for the Human Disease
Monday February 9, 7:30 am ET


ST. LOUIS, Feb. 9 /PRNewswire-FirstCall/ -- GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau`s Pink Sheets Symbol GMED) announced today that its treatment approach to viruses, which tones down the host`s immune response rather than trying to kill the virus, should be effective against the bird flu.
ADVERTISEMENT


In humans, some strains of bird flu kill by causing lung failure. At autopsy, the lungs of people who die of bird flu resemble those of people who have died from SARS or influenza A infection, two other lethal viruses in the news this past year.

The lung is invaded by immune cells called macrophages, and the lung`s tiny air sacs get filled up with fluid. Relatively little virus is present. What kills people is therefore an overly exuberant immune response to an entirely new virus, not proliferation of the virus itself.

GenoMed has identified a very early step in the immune response which can be turned off safely and effectively using already existing drugs. The result is fast recovery from viral disease, in other words, a cure.

This approach has already produced prompt recovery from another frequently lethal viral disease, West Nile virus encephalitis. Seven out of eight patients (88%) with West Nile virus encephalitis were cured in an average of 24 hours this past September. This case series, although small, represents the best results so far against West Nile virus encephalitis. These results will be published in the Pharmacogenomics issue of Current Topics in Medicinal Chemistry, a well respected, peer-reviewed medical journal.

For an independent assessment of GenoMed`s West Nile virus results, please see the recent article by Steve Mitchell, UPI Medical Correspondent, available at: http://washingtontimes.com/upi-breaking/20031204-040206-6908…

A safe, effective cure for a viral disease makes killing the reservoir for the virus unnecessary. So a cure for West Nile virus encephalitis makes it less critical to kill mosquitoes. If GenoMed`s approach also cures bird flu, then there will be little reason to slaughter poultry. The same is true for the SARS virus and civet cats in China: a cure makes culling unnecessary.

GenoMed`s "universal vaccine" against most viral diseases involves blocking angiotensin II, using drugs already known to be extremely safe since they have been used in hundreds of millions of patients worldwide since 1980.

Angiotensin II gets the immune response started and keeps it going. Angiotensin I-converting enzyme (ACE), the enzyme which produces angiotensin II, is expressed on macrophages when they become activated. All immune cells, including macrophages, contain receptors for angiotensin II.

Blocking angiotensin II production with a suitable ACE inhibitor, or the action of angiotensin II at its receptors with an angiotensin II receptor blocker (ARB), should therefore tone down the host`s immune response. GenoMed has seen this approach work for several autoimmune diseases over the past year and a half.

The patient`s blood pressure guides whether an ACE inhibitor or an ARB is used. ARB`s at low doses can tone down the immune system without lowering blood pressure at all.

Said Dr. David Moskowitz, GenoMed`s Chief Medical Officer and CEO, "It is impossible to eradicate a virus`s entire animal reservoir. We can`t kill all the birds in the world. Nor is it ethical to quarantine populations for a transmissible virus like SARS when a cure may exist, as it now does. GenoMed`s treatment approach lets us live with new viruses without having to devise a new vaccine against each new strain. This may be bad news for vaccine companies but wonderful news for public health."

Dr. Moskowitz continued, "Anyone can test our approach for themselves; the trial is completely free from our end. This message is especially important for people getting sicker rather than recovering as fast as expected from a flu-like illness."

Dr. Moskowitz concluded, "The Internet now makes it possible for anybody to enroll in our flu trial at any time of day or night anywhere in the world, simply by going to our website (www.genomedics.com) and clicking on `Flu trial.` We`d like people to enter a working email address so that we can follow up with them. Then they`ll be able to download an informed consent to discuss with their physician. The patient`s own physician will prescribe the medication. A family member could easily do this for a child getting worse with the flu, for example."

The drugs GenoMed uses are safe enough to allow for their preventive use, and are available in every corner drug store around the world. Most general practitioners are quite comfortable using them to treat high blood pressure.

About GenoMed

GenoMed, Inc. is a Next Generation Disease Management(TM) company whose mission is to improve the public`s health by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases.

For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-977-0115, FAX [phone], email: [e-mail], or visit GenoMed at www.genomedics.com.

[strategie06]

Zielkurs von 1$ für VC, heute schon bei 0,20!

Swiss-based VC Expects GenoMed Stock To Surpass $1
Wednesday March 3, 7:03 am ET


ST. LOUIS, March 3 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genes to improve patient outcomes, today announced that it has secured potential long-term funding from Pierpoint Investissements SA, a Swiss-based venture capital group registered in the British Virgin Islands.
ADVERTISEMENT


The agreement calls for a minimum annual investment of $500,000, up to a maximum of $2 million in any one year, for each of the next 10 years in exchange for 12-month restricted shares at a modest discount to the market price. For maintaining this level of annual investment, Pierpoint Investissements SA will keep active warrants for an additional 35 million shares. These can only be converted once the share price of GenoMed reaches at least $1.00. To limit dilution, only 7 million warrants will be convertible each year, so that it will take at least five years to convert this block of 35 million warrants to 12-month restricted shares.

Dr. David Moskowitz, GenoMed`s CEO, said, "We believe that we have achieved equity financing that is minimally dilutive and in the best interests of the company and its existing shareholders. Pierpoint clearly believes that our stock will be worth at least $1, as do I. This financing allows us to move forward aggressively with our scientific program, as well as with our marketing strategy to patients and physicians nationwide."

GenoMed also announced today that the United States Patent and Trademark Office has awarded the company two trademarks that it will use in its marketing efforts: "Next Generation Disease Management" and "Clinical Outcomes Improvement Program."

Dr. Moskowitz is a Harvard and Oxford trained physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes.

About GenoMed

GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. The Company is marketing its treatment against what it believes is the major starting point for most age-related diseases.